Recent studies have suggested that sonic Hedgehog (Shh) signaling pathway is aberrantly activated in cancer stem cells (CSCs). A seven-herb Chinese medicinal formula composed of Amorphophallus rivieri Durieu, Oldenlandia diffusa (Wild) Roxb, Scutellaria barbata D. Don, Gynostemma pentaphyllum (Thunb.) Mak and Amomum cardamomum L, i.e. Qingyihuaji (QYHJ) formula, has been shown to inhibit proliferation of pancreatic CSCs by inhibiting Shh signaling pathway and thereby prolong the overall survival of pancreatic cancer patients. Mass spectrometry analysis revealed that baicalein is one of the major compounds of QYHJ formula. The objective of this study was to investigate the role of Shh pathway in pancreatic cancer and to examine the molecular mechanisms of baicalein involved in pancreatic cancer treatment. We examined the effects of baicalein on pancreatic CSCs both in vivo and in vitro. The results indicated that baicalein attenuated the pluripotency of pancreatic CSCs. Then, we investigated the underlying mechanism and found that nuclear transcription factors, such as Sox-2 and Oct-4 as well as members in Shh signaling pathway, e.g. SHH, SMO, and Gli-2, were downregulated after baicalein treatment. Furthermore, silencing Gli-2 expression by small interfering RNA decreased Sox-2 expression and blocked the inhibitory effects of baicalein, suggesting that the effects of baicalein may be mediated through inhibition of Shh pathway. Our results suggested that baicalein, an active compound in QYHJ formula, could suppress the selfrenewal of pancreatic CSCs through inhibition of Shh signaling pathway.
Introduction
Pancreatic cancer is a common malignant tumor in the digestive system, which is notorious for short-term recurrence, propensity to metastasis, and profound resistance to chemotherapy. Cancer stem cells (CSCs) pose a great threat to the treatment of pancreatic cancer [1, 2] . The incidence of pancreatic cancer is obviously rising, with the 5-year relative survival <8% [3] [4] [5] . Recently, observations have identified the prognostic value of CSCs in many malignancies [6] [7] [8] , including acute pancreatic cancer [9] , breast cancer [10] , lung cancer [11] , hepatocellular carcinoma [12] , and colorectal cancer [13] . Thus, it is of great value to develop potential therapeutic targets against CSCs to reduce tumor progression and metastasis [14, 15] .
Over the past decades, it has been indicated that the sonic Hedgehog (Shh) pathway, a crucial regulator of proliferation and differentiation during embryonic development [16, 17] , might be aberrantly activated in many solid tumors, including human pancreatic cancer [18, 19] . However, the regulation of Shh signaling pathway in pancreatic CSCs is a highly complex mechanism, and the key points remain poorly understood. In vitro study showed that Shh signaling was reconciled by two transmembrane receptors, Protein Patched Homolog 1 (PTCH1) and Smoothened (SMO), while the downstream substrates of Shh signaling pathway were regulated by transcription factors Gli-1, Gli-2, and Gli-3 [20] [21] [22] . Therefore, activation of Shh signaling pathway is involved in the regulation of pancreatic CSCs [23, 24] .
The seven-herb Chinese medicinal formula, Qingyihuaji (QYHJ) formula, was widely used for the treatment of pancreatic cancer abiding by TCM theory and clinical practice in Cancer Hospital, Fudan University (Shanghai, China) during the past decades [25] [26] [27] . TCM theory refers to multi-means treatment of traditional Chinese medicine. During the treatment, clearing up heat-dampness is the basic principle, which is the main pathogenesis of pancreatic cancer based on TCM theory. Our previous clinical studies suggested that the median survival time for patients with advanced and metastatic pancreatic cancer treated with QYHJ formula could be prolonged to 7.6 months with a satisfied quality of life [28] [29] [30] . QYHJ formula significantly suppressed proliferation of pancreatic CSCs via inhibiting Shh signaling pathway [31] . Mass spectrometry analysis showed that baicalein is one of the major compounds of QYHJ formula. As a widely used Chinese herbal medicine extracted from Scutellaria barbata D. Don, baicalein possesses extensive pharmacological activities and has been used in anti-inflammatory and anti-cancer therapies for a long time [32, 33] . Previous studies showed that baicalein could inhibit proliferation of five human pancreatic cell lines (BxPC-3, HPAF, MiaPaca-2, Capan-2, and PANC-1) and induce apoptosis both in vivo and in vitro [34] .
Our study was aimed to explore the therapeutic effect of baicalein on pancreatic CSCs. To this end, we established pancreatic CSC xenograft model to explore the in vivo effect of baicalein on pancreatic cancer. We addressed the potential mechanisms of the inhibitory effect of baicalein on pancreatic CSCs, and focused on the Shh pathway. Our results also illuminated the possible mechanism underlying the longterm survival benefit from QYHJ formula, which verified its potential role as a complementary medicine for pancreatic cancer treatment.
Materials and Methods

Ethics statement
Female BALB/c nude mice (5-or 6-week-old, 16-20 g) were supplied by the Shanghai Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). This experiment was conducted in accordance with the guidelines of the National Institutes of Health for the Care and Use of Laboratory Animals. The protocol was also approved by the Committee on the Use of Live Animals in Teaching and Research, Fudan University.
Reagents and cell culture
Antibodies used in this article were purchased from Cell Signaling Technology (Danvers, USA). Baicalein herb powder, a component of QYHJ formula, was purchased from the Institute of Standard Chinese Medicine (Shanghai, China).
The human pancreatic cancer cell lines, PANC-1, BxPC-3, and SW1990 were obtained from the American Type Culture Collection (Manassas, USA) and cultured in RPMI 1640 medium (Hyclone, Logan, USA) supplemented with 10% fetal bovine serum (FBS; Gibco, New York, USA) and 1% penicillin/streptomycin (Invitrogen, Carlsbad, USA) as recommended by the manufacturer at 37°C in a humidified 5% CO 2 incubator.
Flow cytometric analysis
PANC-1, BxPC-3, and SW1990 cells were detached from culture dishes with Trypsin-EDTA (Invitrogen) and suspended at 1 × 10 6 cells/ml in RPMI 1640 medium supplemented with 2% FBS. To identify the population of pancreatic CSCs, cells were incubated with anti-CD24-PE or anti-CD44-APC antibody (BD, Franklin Lakes, USA) at 4°C for 20 min. After incubation, the cells were centrifuged immediately for 5 min at 800 g, 4°C, and then washed twice with ice-cold RPMI 1640 medium supplemented with 2% FBS. Finally, cells were analyzed on a flow cytometer (BD) and data were analyzed with BD FACS Vantage software. All experiments were performed in triplicates and independently repeated three times.
Cell viability and apoptosis assays
Cell apoptosis was examined by flow cytometric analysis using human Annexin V-FITC Kit (Invitrogen) according to the manufacturer's protocol. Briefly, cells were trypsinized, washed with phophatebuffered saline (PBS), and resuspended in 100 μl 1× binding buffer. Then, 5 μl Annexin V-FITC and 5 μl propodium iodie were added into the suspension for 10 min protected from light at room temperature. After incubation, cells were analyzed for apoptosis by flow cytometry. Cell viability and cell growth inhibition were determined using Cell Counting Kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's protocol. Approximately 3000 cells were seeded into each well of a 96-well plate. After 12-16 h, cells adhered to the microplate and this was designated as time 0. Subsequently, cell viability was determined using CCK-8 and the viability ratios were calculated with reference to Day 0. For cell cytotoxicity assay,~5000 cells were seeded into each well of a 96-well plate, and then exposed to different concentrations (0, 2, 4, 8, 16, 32, 64, 128, and 256 μM) of baicalein for 24, 48, and 72 h, respectively. Inhibition of cell growth was determined from three separate experiments using CCK-8. The concentration of baicalein that inhibited 50% of the cell viability (IC 50 ) was extrapolated from non-linear least squares curve fitting of the dose-response curves using Graphpad Prism (GraphPad Software, La Jolla, USA). Three duplicate wells were used for all experiments in each test.
Wound-healing assay
The effect of baicalein on cell migration ability was determined by a wound scratch assay [35] . PANC-1 cells were seeded into a 6-well plate at 1 × 10 6 cells/well and cultured to 80%-90% confluence in medium containing 10% FBS before scratch wounds were created using a 200-μl pipette tip. After the scratch, PANC-1 cells were then incubated in serum-free medium with or without baicalein (37.27 μM). Images were taken at 0, 24, 48, and 72 h. The cell migration was assessed by measuring the gap size in at least six fields using ImageJ (National Institute of Mental Health, Bethesda, USA). Three duplicates were used for each assay and each one was independently repeated three times.
Sphere forming assay
Spheroid forming assays were performed as described previously [36] . In brief, 1000 cells were plated into each well of 6-well ultralow attachment plates (Corning Co., Corning, USA) in DMEM/F12 supplemented with 1% N2 Supplement (Invitrogen), 2% B27 Supplement (Invitrogen), 20 ng/ml human platelet growth factor (Invitrogen), 20 ng/ml epidermal growth factor (Millipore, Billerica, USA) and 1% antibiotic-antimycotic (Invitrogen) at 37°C with 5% CO 2 . Cells were treated with baicalein (42.16 μM) for 7 days. Spheroids were then photographed and collected after dissociation with Accutase (Innovative Cell Technologies, San Diego, USA). The cells obtained from dissociation were sieved through a 40-μm filter, and counted by coulter counter using trypan blue assay. Three duplicates were used for each assay and each one was independently repeated three times.
Colony formation assay
PANC-1 stem cells were seeded in 6-well plates at a density of 500 cells per well. After cell adhesion, cells were treated with baicalein (42.16 μM) for 10-14 days. After colonies were formed, cells were fixed with 4% formaldehyde and stained with 1% crystal violet, and surviving colonies of >50 cells were scored under a dissection microscope. Three duplicates were used for each assay and each one was independently repeated three times.
Western blot analysis
After treatment with indicated concentrations of baicalein or dimethyl sulfoxide (DMSO), cell lysates were collected and subject to western blot analysis as previously described [35] . Briefly, whole cell protein lysates were extracted using cell lysis buffer (Cell Signaling Technology). BCA protein assay regent (Beyotime biotechnology, Shanghai, China) was used to measure protein concentration. Equal amount of proteins were separated by SDS-PAGE and then transferred to a polyvinylidene fluoride membrane (Millipore). The membranes were blocked with 5% skim milk in PBS-Tween 20 (PBST) at room temperature for 1 h. Then the membranes were incubated with indicated primary antibodies (Proteintech, Wuhan, China) at 4°C overnight. After that, the membranes were washed with PBST, and incubated with horseradish peroxidase-conjugated secondary antibodies (Proteintech). After washing, the signals were developed using chemiluminescent kit and detected using a LAS-4000 mini CCD camera (GE healthcare, Marlborough, USA).
Small interfering RNA transfection
Small interfering RNA (siRNA) against human Gli-2 was synthesized by GenePharma (Shanghai, China). The sequence of siRNA against Gli-2 was 5′-GATCTGGACAGGGATGACT-3′. The sequence of control siRNA was 5′-GATCTGGACACCCATGACT-3′. PANC-1 stem cells were selected by flow cytometric analysis as described above. For the transfection procedure, PANC-1 stem cells were seeded in 6-well culture plates in RPMI 1640 medium containing 5% FBS, grown to 70% confluence. Gli-2 and control siRNAs were transfected into cells using the lipofectamine 2000 reagent (Thermo Fisher Scientific, Waltham, USA) according to the manufacturer's instructions. Briefly, lipofectamine 2000 was incubated with Opti-MEM medium (Invitrogen) for 5 min, mixed with siRNA (up to 50 nM), and incubated for 20 min at room temperature before the mixture was added into the cells. After 6-8 h of culture, cells were washed and resuspended in fresh media with or without baicalein and cultured for an additional 24 h for subsequent experiments.
Immunofluorescence analysis
For the immunofluorescence staining, cells were fixed with 4% paraformaldehyde and permeabilized using 0.3% Triton-100 for 15 min. After being washed with PBS for 5 min three times, cells
were then blocked for 1 h, followed by incubation with anti-Oct-4 (rabbit polyclonal, 1:200 dilution) and anti-Sox-2 (rabbit polyclonal, 1:200 dilution) antibodies at 4°C overnight. After wash with PBS for 5 min three times, cells were then incubated with Alexa Flor 488-conjugated goat-anti-rabbit immunoglobulin G (1:200 dilution; Proteintech) for 2 h at 37°C. Finally, the cells were washed and mounted with mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Southern Biotech, Birmingham, USA). A negative control in which the primary antibody was omitted was used to test for antibody specificity. Images were captured using a confocal fluorescence microscope (Leica, Wetzlar, Germany).
Animal treatment
Twenty-four female BALB/c nude mice were randomly divided into three groups and assigned to each treatment and control group. Animals were housed eight per cage under specific pathogen-free and temperature-light-controlled conditions (20-23°C, 12 h light/ 12 h dark cycle). Animals had free access to food and water ad libitum. All mice were acclimatized for 1 week before the experiment.
Establishment of xenograft tumor models
Xenograft tumor models were established as previously described [35] . PANC-1 stem cells were sorted by flow cytometer as described above. Briefly, 5 × 10 4 PANC-1 stem cells in logarithmic phase were injected subcutaneously into the right flank of each female BALB/c nude mouse. Baicalein was dissolved in PBS and administered orally via gavage to mice in the treatment groups for 2 weeks at dose of 20 or 60 mg/kg body weight daily. Control group was treated similarly but received vehicle only. Animals were monitored by observing the movement and fur and measuring body weight twice a week. The length and width of the tumors (mm) were measured every other day using calipers. Tumor volume was calculated using the formula (a×b 2 ) × 0.5 where a and b are the long and short dimensions, respectively. At the end of the experiment, mice were euthanatized by decapitation. The tumors were isolated from the bodies and weighed and then subject to immunohistochemistry (IHC) analysis accordingly.
Immunohistochemistry analysis
IHC analysis was performed as described previously [37] . Briefly, specimens of tumor tissue were fixed in 10% formalin and embedded in paraffin wax. 
Statistical analysis
ANOVA and Student's t-tests were used to determine the statistical significance of differences between samples, and the results are expressed as the mean ± standard deviation (SD). A value of P < 0.05 was considered statistically significant. All experiments were independently repeated at least three times. All statistical analyses were performed using the Graphpad Prism software version 6.0.
Results
Baicalein inhibits cell proliferation and affects cell migration of pancreatic cancer cells
We first detected the effect of baicalein on cell growth in human PANC-1 pancreatic cancer cells by CCK-8 assay. When compared with the control group, baicalein treatment was shown to significantly inhibit PANC-1 cell proliferation at various concentrations (2, 4, 8, 16, 32, 64, 128 , and 256 μM) for 48 and 72 h (P < 0.05). At 24 h, the inhibition rate was increased with the increase of drug concentration, but it was not statistically significant. With the increase of administration time and increase in drug concentration, the inhibitory effect of baicalein on the proliferation of PANC-1 cells was gradually increased in a time-and dose-dependent manner (P < 0.05), as shown in Fig. 1A . The IC 50 value was determined to be 37.27 μM when treated with baicalein for 48 h (Fig. 1B) . Detection of the cell migration capacity is also a method for analyzing the metastatic potential of tumor cells. We then detected the effect of baicalein on cell migration of PANC-1 cells. As shown in Fig. 1C , the number of cells migrated into the scratch area was significantly lower when treated with baicalein compared with the control group.
Selection of experimental pancreatic CSC cell lines
In order to select the appropriate pancreatic CSCs for the experiment, we detected CD44
+ cells in three pancreatic cancer cell lines, PANC-1, BxPC-3, and SW1990. As shown in Fig. 2A , the percentages of CD44 + CD24 + cells in three cell lines were 12.8%, 8.9%, and 4.4%, respectively. To evaluate the possibility that Shh signaling pathway is active in human pancreatic CSCs, we determined the expression of Shh signaling pathway (SHH, PTCH1, SMO, Gli-1, Gli-2, and Gli-3) in these three pancreatic cancer cell lines by western blot analysis (Fig. 2B) . The results showed that PANC-1 cell line has a relatively high stem cell potential, so we chose PANC-1 cell line for the subsequent experiments. CD44 + CD24 + cells were selected from PANC-1 cells and cultured for 7 days, and the morphologies of PANC-1 cells are shown in Fig. 2C . Furthermore, we compared the expression of the Shh pathway in CSCs and non-CSCs selected from PANC-1 cells. The results showed that Shh pathway was highly activated in CSCs, indicated by elevated expression of SHH, PTCH1, SMO, Gli-1, Gli-2, and Gli-3 (Fig. 2D) .
Baicalein inhibits the cell proliferation and affects sphere formation of pancreatic CSCs
We next detected the effect of baicalein on inhibition of pancreatic CSC proliferation by CCK-8 assay. Pancreatic CSCs were treated with various concentrations of baicalein (2, 4, 8, 16, 32, 64, 128, and 256 μM). At 24 h, the inhibition rate increased with an increase in drug concentration. With the increase of administration time and increase in drug concentration, the inhibitory effect of baicalein on the proliferation of PANC-1 CSCs was gradually increased in a time-and dose-dependent manner (P < 0.05), as shown in Fig. 3A .
The IC 50 value was determined to be 42.16 μM when treated with baicalein for 48 h (Fig. 3B) (Fig. 3D) . To assess the effect of baicalein on the pluripotency of pancreatic CSCs, sphere formation and colony formation assays were performed on pancreatic CSCs. As shown in Fig. 3E ,F, the percentages of spheres and colonies were significantly reduced after treatment with baicalein and the decrease was in a dose-dependent manner. These data indicated that baicalein has an inhibitory effect on pancreatic CSCs.
Baicalein suppresses the expression of pluripotency maintaining factors in pancreatic CSCs in vitro
Recent studies demonstrated that markers of pancreatic CSCs, such as CD24, CD44, CD133, Oct-4, Sox-2, and Nanog, are highly expressed in pancreatic CSCs compared with those in pancreatic cancer cells, which is the main reason for drug resistance. We then examined the effect of baicalein on the markers of CSCs isolated from PANC-1 cells by western blot analysis. As shown in Fig. 4A , the levels of CD44 and CD24 were significantly reduced after treatment with baicalein; furthermore, the levels of Oct-4 and Sox-2 were also greatly reduced. The transcription factors, Oct-4, Sox-2, and Nanog are highly expressed in stem cells, which is essential to retain the pluripotency of stem cells. Based on the results in Fig. 4A , we further detected the nuclear expression of Oct-4 and Sox-2 by immunofluorescence staining. Results showed that the nuclear expressions of Oct-4 and Sox-2 were also inhibited after treatment with baicalein (Fig. 4B,C) . These data indicated that baicalein may reduce the pluripotency potential in pancreatic CSCs.
Baicalein inhibits Hedgehog signaling pathway in pancreatic CSCs in vitro
The Hedgehog signaling pathway is essential for the development of tissues and organs [19] . Thus, we examined the effect of baicalein on the Shh pathway by measuring the expression of Shh receptors (PTCH1 and SMO) and effectors (Gli-1, Gli-2, and Gli-3) in pancreatic CSCs. As shown in Fig. 5A , baicalein inhibited the Shh pathway in pancreatic CSCs. As Gli-1 and Gli-2 play a central role in Shh signaling pathway, we further detected the nuclear expression of Gli-1 and Gli-2 by immunofluorescence staining. Results showed that the nuclear expression of Gli-2 was inhibited after treatment with baicalein, while baicalein had little effect on the nuclear expression of Gli-1 (Fig. 5B,C) .
Inhibition of Gli-2 attenuates the effect of baicalein on pancreatic CSCs in vitro
As the Hedgehog signaling pathway is required in maintaining CSCs, we therefore investigated whether Hedgehog blockade by formation assay showed that baicalein reduced sphere formation ability of pancreatic CSCs in a dose-dependent manner. (F) Colony formation assay showed that baicalein reduced colony formation ability of pancreatic CSCs in a dose-dependent manner. Data were presented as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. baicalein could affect the pluripotency of pancreatic CSCs. We demonstrated that baicalein could robustly reduce Gli-2 expression, thus we sought to inhibit the Shh signaling pathway by knocking down Gli-2 using siRNA. The expression of Gli-2 in pancreatic CSCs was almost completely suppressed by Gli-2 siRNA as revealed by western blot analysis (Fig. 6A) . Then, we investigated the effect of baicalein on the pluripotency of pancreatic CSCs and Gli-2-silenced CSCs by performing sphere formation and colony formation assays. As shown in Fig. 6B ,C, baicalein suppressed the ability of sphere formation and colony formation in pancreatic CSCs, but had no effect on Gli-2-silenced CSCs. Furthermore, in Gli-2-silenced CSCs, baicalein had little effect on cell apoptosis (Fig. 6D) . Taken together, these results suggested that the effect of baicalein on pluripotency of pancreatic CSCs was mainly through downregulating Gli-2.
Baicalein treatment inhibits the progression of pancreatic CSCs in vivo
To confirm the effect of baicalein on pancreatic CSCs in vivo, we established mouse xenograft models using PANC-1 stem cells. PANC-1 stem cells were selected by flow cytometric analysis.
Twenty-four female BALB/c nude mice were subcutaneously injected with PANC-1 stem cells (5 × 10 4 cells/mouse). After tumor formation (7 days after cell injection), mice were randomly divided into three groups, and each group was treated with indicated doses of baicalein, the low-dose group (20 mg/kg, gavage, 0.2 ml/day), the high-dose group (60 mg/kg, gavage, 0.2 ml/day), or PBS (gavage, 0.2 ml/day) as a control, respectively. The treatment lasted for 14 days (Fig. 7A) . The tumor weight was 1.96 ± 0.20 g in the control group, 1.69 ± 0.13 g in the low-dose baicalein group, and 0.75 ± 0.11 g in the high-dose baicalein group (Fig. 7B) . It was found that baicalein treatment resulted in a reduced tumor growth in nude mice (Fig. 7C, upper panel) . In addition, tumor growth curve showed that baicalein reduced the growth of tumors induced by the pancreatic CSC injection, which is in agreement with in vitro results (Fig. 7C, lower panel) . However, baicalein had little effect on the body weight of tumor-bearing mice ( Fig. 7D, P = NS) . Moreover, IHC analysis confirmed that tumor tissues treated with baicalein exhibited reduced expression of stem cell markers and low level of Shh pathway receptors and effectors (Fig. 8A,B) . Therefore, our results suggest that baicalein may attenuate the proliferation and pluripotency of pancreatic CSCs in vivo through inhibiting the Shh pathway. 
Discussion
At present, effective medication and drugs are lacking for the treatment of pancreatic cancer which is notorious for its resistance to chemo-radio-therapy [10, 11] . Features attributed to CSCs play a vital role in the proliferation, differentiation, and metastasis of tumor. Aberrant activation of signaling pathways involved in cancer progression extensively occurred in pancreatic CSCs, including Shh pathway. Inhibition of Shh pathway has been shown to suppress human pancreatic CSC pluripotency characteristics [38, 39] . Baicalein, a flavone present in S. barbata D. Don, possesses extensive pharmacological activities, and has been widely studied in several malignancies and shown to be particularly effective against several cancers in both in vitro and in vivo studies [40] [41] [42] [43] . Several recent studies demonstrated a beneficial effect of baicalein in suppressing pancreatic cancer cells [34, 44, 45] . These studies suggested that baicalein could be a potential agent for chemoprevention against pancreatic cancer. However, as far as we know, the effects of baicalein on the growth inhibition and induction of apoptosis in pancreatic CSCs have not been explored and the role of Shh pathway in regulating pancreatic CSCs remains unclear.
In a previous study, we found that QYHJ formula inhibited Shh signaling pathway in pancreatic CSCs [38] . Additionally, baicalein was found to be one of the major compounds in QYHJ formula by mass spectrometry analysis. Based on these results, we examined the role of baicalein on the pancreatic CSCs, and found that baicalein is of great value in maintaining pluripotency of CSCs (e.g. self-renewing, differentiation, transfer, etc.), providing insights into the anti-neoplastic therapy of TCM.
In the present study, we reported that baicalein could inhibit the proliferation and pluripotency of pancreatic CSCs. First, we found that baicalein could inhibit cell growth in a dose-dependent manner. The ability of sphere formation and colony formation was also significantly reduced by baicalein. Furthermore, western blot analysis of stem cell markers showed that the expressions of CD24, CD44, Oct-4, and Sox-2 were also greatly repressed by baicalein. Third, baicalein inhibited the expression of components in Shh signaling pathway. The influence of Hedgehog pathway on CSCs has been found in various human tumors [46] . As one of the most important transcription factors in Shh signaling pathway, Gli-2 was also dramatically reduced in the nuclear by baicalein. The inhibitory effects of baicalein were reconciled by silencing Gli-2 expression in pancreatic CSCs, and the baicalein-induced apoptosis was also reduced. The results were also confirmed in another cell line BxPC-3 ( Supplementary Fig. S1 ). The in vivo experiments using xenograft tumor model suggested the in vivo efficacy of baicalein on pancreatic cancer.
Taken together, our present results indicated that, as an active compound in QYHJ formula, baicalein inhibited human pancreatic CSC proliferation, induced pancreatic CSC apoptosis and suppressed the self-renewal of pancreatic CSCs through inhibition of Shh signaling pathway. This study highlights the therapeutic potential of baicalein against pancreatic CSCs and prompts further studies The body weight of mice was recorded weekly. *P < 0.05, **P < 0.01, ****P < 0.0001. NS, not significant.
to explore the efficacy of baicalein in combination with other putative therapies for pancreatic cancer treatment.
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